New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 10, 2014
08:46 EDTONVOOrganovo says technology successfully fabricated 3D breast tissues in study
Organovo Holdings updated investors on the results of its initial study of 3D breast tissues generated with its NovoGen MMX Bioprinter in breast cancer models. The company presented these results at the annual meeting of the American Association for Cancer Research, or AACR, held on April 5-9. Results from the company’s initial study showed the NovoGen MMX Bioprinter technology can successfully fabricate 3D breast tissues consisting of cancer cells, fibrous stroma, adipose tissue, and microvasculature on a reproducible basis. Histologic and metabolic measurements highlighted a consistency in printing from construct to construct. The company’s experiments involving the delivery of fluorescently-tagged drugs to its 3D breast tissues indicate some drugs like methotrexate, which is small and hydrophilic, can fully penetrate its 3D bioprinted tissues, allowing assessment of the effects of drugs throughout the full thickness of the tissue. Other drugs, like paclitaxel, which is large and lipophilic, which are known to have trouble penetrating solid tumors due to dense stroma presence, charge, or other factors, are similarly modeled in the company’s 3D breast tissues. These early results from the company’s initial study confirm that the 2D culture systems were not effective in modeling drug responses in complex, multi-cellular tissue systems, like breast cancer. Furthermore, these early results suggest that utilizing 3D tissues may enable researchers to make compartment-specific assessments of drug response — something that is not currently possible outside of in vivo models to date.
News For ONVO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for ONVO

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use